2008 - Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction

Ezekowitz, Justin A.; McAlister, Finlay A.
May 2009
ACP Journal Club;5/19/2009, Vol. 150 Issue 5, p8
Academic Journal
The article cites a study to find out whether irbesartan reduces mortality and cardiovascular (CV) morbidity in patients with heart failure (HF) and preserved ejection fraction (PEF). The study was conducted on 4128 patients of 60 years of age with left ventricular ejection fraction. The study found that the irbesartan and placebo groups did not differ for the primary composite endpoint.


Related Articles

  • STUDY CONCLUSIONS AND IMPLICATIONS FOR GERIATRIC CLINICAL PRACTICE.  // Journal of Gerontological Nursing;Jan2004, Vol. 30 Issue 1, p5 

    Presents several study conclusions and their implications for geriatric clinical practice. Efficacy of Simvastatin 40 mg in reducing all-cause mortality and coronary heart disease-related death in high-risk individuals compared to placebo; Association of estrogen/progestin treatment in healthy...

  • Combination ezetimibe and simvastatin lowers LDL cholesterol to a greater extent than rosuvastatin at various doses. Catapano, A. L.; Davidson, M. H.; Ballantyne, C. M. // Formulary;Jan2007, Vol. 42 Issue 1, p39 

    The article presents a study on the combination therapy with ezetimibe and simvastatin for reduction of low-density lipoprotein cholesterol to the patients with heart disease. The researchers assessed the patients after a 4-week placebo and diet run-in period and 6 weeks of active drug therapy....

  • Cardio meds gain favor. Johnsen, Michael // Drug Store News;11/22/2004, Vol. 26 Issue 16, p22 

    Focuses on the report which states that patients with heart failure can benefit from prescriptions for cardiovascular medicine upon discharge from hospitals. Death rate for heart failure patients; Benefits of continuation of statin prescriptions; Complications among patients who had stopped...

  • Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure: COMMENTARY. Furberg, Curt D.; Psaty, Bruce M. // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p5 

    This article focuses on a study regarding comparison of drugs carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure, published in the 2003 issue of the journal "Lancet." The treatment of chronic heart failure is a crowded field with multiple choices, both between...

  • A REVIEW ON EFFECT OF COENZYME Q10 ON CARDIAC HEART FAILURE. Chandra, Suresh; Sahu, Shachi; Maurya, Mangla // Pharma Science Monitor;Apr2013, Vol. 4 Issue 2, p3820 

    This article provides a comprehensive review of 30 years of research on the use of coenzyme Q10 in prevention and treatment of cardiovascular disease. This endogenous antioxidant has potential for use in prevention and treatment of cardiovascular disease, particularly hypertension,...

  • Statins in the Treatment of Chronic Heart Failure: A Systematic Review. van der Harst, Pim; Voors, Adriaan A.; van Gilst, Wiek H.; Böhm, Michael; Veldhuisen, Dirk J. van // PLoS Medicine;Aug2006, Vol. 3 Issue 8, pe333 

    Background:The efficacy of statin therapy in patients with established chronic heart failure (CHF) is a subject of much debate.Methods and Findings:We conducted three systematic literature searches to assess the evidence supporting the prescription of statins in CHF. First, we investigated the...

  • Placebo Therapy and the Law: Prescribe with Care*. Kapp, Marshall B. // American Journal of Law & Medicine;Winter83, Vol. 8 Issue 4, p371 

    The use of placebos by physicians for therapeutic purposes is a common part of clinical medical practice. This Article examines the legal and ethical ramifications of placebo prescription. In particular, ethical concerns are related to substantive legal theories that may be advanced to attack or...

  • Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. van der Meer, P.; Groenveld, H. F.; Januzzi Jr, J. L.; van Veldhuisen, D. J. // Heart;Aug2009, Vol. 95 Issue 16, p18 

    Background: Anaemia is common in patients with chronic heart failure (HF), and erythropoiesis stimulating proteins (ESPs) are frequently used for its treatment. However, recent studies in patients with malignancies and renal failure have raised concerns about the safety of these agents....

  • A Novel Method to Adjust Efficacy Estimates for Uptake of Other Active Treatments in Long-Term Clinical Trials. Simes, John; Voysey, Merryn; O'Connell, Rachel; Glasziou, Paul; Best, James D.; Scott, Russell; Pardy, Christopher; Byth, Karen; Sullivan, David R.; Ehnholm, Christian; Keech, Anthony // PLoS ONE;2010, Vol. 5 Issue 1, p1 

    Background: When rates of uptake of other drugs differ between treatment arms in long-term trials, the true benefit or harm of the treatment may be underestimated. Methods to allow for such contamination have often been limited by failing to preserve the randomization comparisons. In the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics